GB202013728D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB202013728D0
GB202013728D0 GBGB2013728.7A GB202013728A GB202013728D0 GB 202013728 D0 GB202013728 D0 GB 202013728D0 GB 202013728 A GB202013728 A GB 202013728A GB 202013728 D0 GB202013728 D0 GB 202013728D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2013728.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nrg Therapeutics Ltd
Original Assignee
Nrg Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nrg Therapeutics Ltd filed Critical Nrg Therapeutics Ltd
Priority to GBGB2013728.7A priority Critical patent/GB202013728D0/en
Publication of GB202013728D0 publication Critical patent/GB202013728D0/en
Priority to US18/023,558 priority patent/US20240067614A1/en
Priority to CA3190645A priority patent/CA3190645A1/en
Priority to CN202180053567.3A priority patent/CN116096705A/zh
Priority to PCT/GB2021/052261 priority patent/WO2022049376A1/en
Priority to KR1020237007646A priority patent/KR20230069915A/ko
Priority to ES21769789T priority patent/ES3055772T3/es
Priority to EP21769789.5A priority patent/EP4208442B1/en
Priority to MX2023002525A priority patent/MX2023002525A/es
Priority to IL300900A priority patent/IL300900A/en
Priority to JP2023537723A priority patent/JP7784430B2/ja
Priority to AU2021337195A priority patent/AU2021337195A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB2013728.7A 2020-09-01 2020-09-01 Novel compounds Ceased GB202013728D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB2013728.7A GB202013728D0 (en) 2020-09-01 2020-09-01 Novel compounds
AU2021337195A AU2021337195A1 (en) 2020-09-01 2021-09-01 Novel compounds
PCT/GB2021/052261 WO2022049376A1 (en) 2020-09-01 2021-09-01 Novel compounds
CA3190645A CA3190645A1 (en) 2020-09-01 2021-09-01 Novel compounds
CN202180053567.3A CN116096705A (zh) 2020-09-01 2021-09-01 新型化合物
US18/023,558 US20240067614A1 (en) 2020-09-01 2021-09-01 Novel compounds
KR1020237007646A KR20230069915A (ko) 2020-09-01 2021-09-01 신규 화합물
ES21769789T ES3055772T3 (en) 2020-09-01 2021-09-01 Mptp inhibitors
EP21769789.5A EP4208442B1 (en) 2020-09-01 2021-09-01 Mptp inhibitors
MX2023002525A MX2023002525A (es) 2020-09-01 2021-09-01 Nuevos compuestos.
IL300900A IL300900A (en) 2020-09-01 2021-09-01 new compounds
JP2023537723A JP7784430B2 (ja) 2020-09-01 2021-09-01 新規化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2013728.7A GB202013728D0 (en) 2020-09-01 2020-09-01 Novel compounds

Publications (1)

Publication Number Publication Date
GB202013728D0 true GB202013728D0 (en) 2020-10-14

Family

ID=72749708

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2013728.7A Ceased GB202013728D0 (en) 2020-09-01 2020-09-01 Novel compounds

Country Status (12)

Country Link
US (1) US20240067614A1 (https=)
EP (1) EP4208442B1 (https=)
JP (1) JP7784430B2 (https=)
KR (1) KR20230069915A (https=)
CN (1) CN116096705A (https=)
AU (1) AU2021337195A1 (https=)
CA (1) CA3190645A1 (https=)
ES (1) ES3055772T3 (https=)
GB (1) GB202013728D0 (https=)
IL (1) IL300900A (https=)
MX (1) MX2023002525A (https=)
WO (1) WO2022049376A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202013731D0 (en) * 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel cmpounds
EP4514780A4 (en) * 2022-04-29 2026-04-29 Dong A St Co Ltd BICYCLIC COMPOUNDS USED AS TEAD INHIBITORS
GB202300833D0 (en) 2023-01-19 2023-03-08 Nrg Therapeutics Ltd Novel compounds
CN119306612B (zh) * 2023-07-14 2026-03-20 中国科学院大连化学物理研究所 一种反式氨基茚满的制备方法
CN121866248A (zh) 2023-09-05 2026-04-14 Nrg治疗有限公司 作为mptp抑制剂起作用的吡啶衍生物
GB202410534D0 (en) 2024-07-18 2024-09-04 Nrg Therapeutics Ltd Novel method and uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
US7482488B2 (en) * 2002-08-29 2009-01-27 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
JP2006160916A (ja) * 2004-12-08 2006-06-22 Fuji Photo Film Co Ltd インクジェット用インク組成物及びインクジェット記録方法
EP2179984A1 (en) * 2008-10-27 2010-04-28 Congenia S.r.l. Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
DK2669270T3 (en) * 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
US10155936B2 (en) * 2014-12-05 2018-12-18 An2H Discovery Limited Parkin ligase activation methods and compositions
CA2884607A1 (en) 2015-03-11 2016-09-11 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
GB202013731D0 (en) * 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel cmpounds

Also Published As

Publication number Publication date
MX2023002525A (es) 2023-05-17
WO2022049376A1 (en) 2022-03-10
EP4208442A1 (en) 2023-07-12
JP7784430B2 (ja) 2025-12-11
EP4208442C0 (en) 2025-10-22
US20240067614A1 (en) 2024-02-29
IL300900A (en) 2023-04-01
CN116096705A (zh) 2023-05-09
EP4208442B1 (en) 2025-10-22
AU2021337195A1 (en) 2023-03-02
JP2023539694A (ja) 2023-09-15
KR20230069915A (ko) 2023-05-19
CA3190645A1 (en) 2022-03-10
ES3055772T3 (en) 2026-02-16

Similar Documents

Publication Publication Date Title
GB202013728D0 (en) Novel compounds
GB2637108B (en) Novel Compounds
GB202115158D0 (en) Novel compounds
GB202008749D0 (en) Novel compounds
GB202115156D0 (en) Novel compounds
GB202016800D0 (en) Novel compounds
GB202115150D0 (en) Novel compounds
GB202101734D0 (en) Novel Compounds
GB202106872D0 (en) Novel compounds
GB202106871D0 (en) Novel compounds
GB202014341D0 (en) Novel compounds
GB202409732D0 (en) Novel compounds
GB202118096D0 (en) Novel compounds
GB202117366D0 (en) Novel compounds
GB202113016D0 (en) Novel compounds
GB202108873D0 (en) Novel compounds
GB202101935D0 (en) Novel compounds
GB202101573D0 (en) Novel compounds
GB202101280D0 (en) Novel compounds
GB202019590D0 (en) Novel Compounds
GB202019588D0 (en) Novel Compounds
GB202016791D0 (en) Novel compounds
GB202016758D0 (en) Novel compounds
GB202016709D0 (en) Novel compounds
GB202016689D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)